On 7 May 2019, Lonza will host a free 60-minute webinar during whichAdaptimmune Therapeutics will explain their decision to move to a paperless QC microbiology laboratory
Walkersville, MD (USA) / Basel (CH), 23 April 2019 – On 7 May 2019, Lonza will host a free 60-minute webinar during which Adaptimmune Therapeutics will explain their decision to move to a paperless QC microbiology laboratory. They will also describe the implementation of Lonza’s paperless MODA™ QC Micro Solution to streamline productivity and drive efficiencies.
Processing large volumes of samples from multiple sources and managing the abundance of generated data can prove particularly challenging for QC microbiology laboratories. With increasing focus on the importance of data integrity and automation, many organizations are moving to paperless solutions to capture, process and manage information more efficiently and reduce the potential for errors commonly associated with paper-based processes. Paperless systems also allow for real-time access to data, enabling faster and more informed decisions.
Titled “Adaptimmune: Implementing a Paperless QC Micro Laboratory,” the webinar will be presented by Staci Williams, Senior Microbiologist at Adaptimmune. During the webinar she will discuss:
· Considerations driving the decision to implement a computerized system
· Relevant regulatory requirements
· The impact of the solution on QC processes
· Benefits of the review-by-exception approach
· How the system has streamlined environmental monitoring investigations
More information about attending the webinar is available here.
Date: Tuesday, 7 May 2019
8 AM PDT (Los Angeles)
11 AM EDT (New York)
4 PM BST (London)
5 PM CEST (Berlin)
Further information can be found on the MODA™ QC Micro Solution product page. By registering interest in the webinar, participants will also receive a link once it is available to view the webinar “on demand” via the Lonza website.
More information about Lonza’s upcoming and on-demand webinars is available here: www.lonza.com/webinars.
About Lonza
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Lonza Contact Information
Petra Haberkamm
Manager Marketing Communications
Lonza Cologne GmbH
Tel +49 221 991990
petra.haberkamm@lonza.com
Constance Ward
Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
